{"entity":{"id":"nct07561463","kind":"trial","name":"Sacituzumab Tirumotecan for Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of sacituzumab tirumotecan in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","summary":"Sacituzumab Tirumotecan for Pancreatic Cancer is a phase 2, interventional study registered as NCT07561463 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 30 participants, started 2026-04-01 and due to reach its primary completion in 2027-01-01. Interventions recorded: Sacituzumab tirumotecan. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (including adenosquamous carcinoma)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07561463","url":"https://clinicaltrials.gov/study/NCT07561463"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-tirumotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07561463","phase":"2","setting":"A Phase II Trial of Sacituzumab Tirumotecan for Previously Treated Locally Advanced or Metastatic Pancreatic Cancer","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07561463/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}